Enteric coated tablet: A total of 75-150 mg daily given in two or three divided doses.
Sustained release tablets: One tablet daily, taken whole with liquid, preferably during meal.
Suppositories: 75-150 mg daily in divided doses.
Gel: Depending on the painful site to be treated, 2-4 g gel may be applied 3-4 times daily.
Enteric coated tablet: 1-3 mg/kg per day in divided doses.
Sustained release tablets: Not recommended.
Suppositories: 1-3 mg/kg body weight in divided doses.
Each 3 ml ampoule contains Diclofenac Sodium 75 mg & each 2 ml ampoule contains Diclofenac Sodium 75 mg and Lidocaine Hydrochloride 20 mg .
Adults: One ampoule once (or in severe cases, twice) daily by intramuscular injection.
Renal colic: One ampoule once daily intramuscularly. A further ampoule may be administered after 30 minutes, if necessary. The recommended maximum daily dose of diclofenac is 150 mg, by any route. The recommended maximum daily dose of lidocaine is 200 mg.
Children: In juvenile chronic arthritis, 1-3 mg of diclofenac/kg body wt. daily in divided doses.
Elderly patients: In elderly or debilitated patients, the lowest effective dosage is recommended, commensurate with age and physical status.
May increase serum levels of methotrexate. Concomitant use with other NSAIDs or anticoagulants (e.g. warfarin) is associated with higher risk of GI bleeding. Increased risk of nephrotoxicity with ciclosporin or triamterene. May increase the risk of developing corneal complications in patients with significant pre-existing corneal inflammation when use concomitantly with ophth preparation containing corticosteroids. Colestyramine and colestipol reduce the bioavailability of diclofenac. Decreased plasma concentration when administered after sucralfate. Ophth application of diclofenac may reduce the efficacy of ophth acetylcholine and carbachol. May increase serum levels of lithium and digoxin.
It is contra-indicated for those patients who are hypersensitive to Diclofenac. In patients with active or suspected peptic ulcer or gastrointestinal bleeding, or for those patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by aspirin or other NSAIDs possessing prostaglandin synthetase inhibitinig activity, it is also contraindicated.
Because of the presence of Lidocaine, it is also contraindicated for those patients who are hypersensitive to local anaesthetics of the amide type, although the incidence is very rare.
Side-effects of Diclofenac is usually mild and transient. It is generally well tolerated. At the starting of the treatment, however, patients may sometimes complain of gastrointestinal discomfort, epigastria pain, eructation, nausea and Diarrhoea, headache and bleeding sometime may occur. Occasionally skin rash, peripheral oedema and abnormalities of serum transaminase have been reported.Very rarely reported side effects include activation of peptic ulcer, haematemesis or melena, blood dyscrasia (extensive usage). There have been isolated reports of anaphylactoid reactions. The adverse effects due to Lidocaine mainly involve the CNS, are usually of short duration, and are dose related. The CNS reaction may be manifested by drowsiness, dizziness, disorientation, confusion, lightheadness, etc. Incase of eye drops ocular burning sensation or allergic reaction may occur in 5-10% patients.
Pregnancy: Diclofenac tablets and injection should not be prescribed during pregnancy, unless there are compelling reasons for doing so. The lowest effective dosage should be used. This type of drugs are not recommended during the last trimester of pregnancy. Very small quantities of Diclofenac may be detected in breast milk, but no undesirable effects on the infant are to be expected. Since no experience has been acquired with Diclofenac gel in pregnancy or lactation, it is not recommended for use in these circumstances.
Lactation: Very small quantities of Diclofenac may be detected in breast milk, but no undesirable effects on the infant are to be expected.
Patients with known CV disease or risk factors for CV disease, fluid retention or heart failure, SLE, HTN, history of GI disease. Patients who may be adversely affected by prolongation of bleeding time. Hepatic and renal impairment. Elderly. Lactation.
Symptoms: Lethargy, drowsiness, nausea, vomiting, epigastric pain, GI bleeding. HTN, acute renal failure, resp depression, anaphylactoid reactions and coma may occur rarely.
Management: Symptomatic and supportive treatment. Immediately empty the stomach by inducing emesis or gastric lavage and admin of activated charcoal may be useful after.
Store in a cool and dry place, protected from light.